Safety and tolerability of MW151 administered with whole-brain radiotherapy in patients with intracranial metastases
Cognitive Dysfunction · Cognitive Disorder
Enrolment: 27 · Results not recorded
Loading the evidence…
Drug
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Cognitive Dysfunction · Cognitive Disorder
Enrolment: 27 · Results not recorded
Drug Toxicity
Enrolment: 40 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Midline fluid percussion injury (diffuse axonal brain injury) of moderate severity at 1.2 plus or minus 0.05 atm
MW151 significantly suppressed injury-induced cortical IL-1 beta at all three doses (0.5 mg/kg p=0.0283, 1.5 mg/kg p=0.0049, 5 mg/kg p=0.0008), with maximal suppression at 1.5 mg/kg and no further gain at 5 mg/kg; a single 5 mg/kg dose at 1 h also suppressed IL-1 beta (p=0.0362). F4/80 and GFAP sta…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.
Model: Midline closed head injury (diffuse traumatic brain injury) using a stereotaxic electromagnetic impactor, 5.0 mm steel tip, velocity 5.0 m/s, dwell time 100 ms, impact depth 1.0 mm at ML 0.0 mm, AP -1.5 mm
A single 5 mg/kg dose at 3 h or 6 h post-injury reduced cortical IL-1beta at the 9 h peak by 58 to 63%, with dose-dependent suppression significant at 5 and 10 mg/kg and no effect on CCL2. Extended dosing (3 h, 6 h then daily for 7 days) rescued radial arm water maze performance and reduced IBA1, C…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.